drugset
drugset / Trial / NCT06134843

Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds

NCT06134843 ↗

Phase 1/2 Unknown 12 enrolled Hobart W. Harris Vitruvian Medical Devices, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study to determine whether the combination biologic/drug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery. Participants will have their skin graft donor sites immediately treated with DERMASEAL versus standard of care wound dressings followed by periodic monitoring of their recovery.

Timeline

Start
2024-09-01
Primary completion
2025-01-31
Completion
2025-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject DERMASEAL Unknown — Topical

Indications

No indication recorded.